Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to developing drugs and therapies focused on nasal delivery of pharmaceutical medications in neurology and infectious diseases. The company is primarily focused on innovative treatments for neurological conditions such as concussions, leveraging intranasal drug delivery technology and neurosteroids like ONP-002. With a history of scientific breakthroughs and strategic acquisitions, Oragenics aims to address critical unmet medical needs through cutting-edge drug delivery systems and therapies, including a pipeline of vaccine candidates and neuroprotective drugs.
Industries
Nr. of Employees
small (1-50)
Oragenics, Inc.
Products
Intranasal neurosteroid lead candidate (clinical-stage)
A first-in-class neurosteroid candidate delivered via an intranasal spray-dried nanoparticle formulation and single-use nasal device intended to provide rapid brain absorption for treatment of mild traumatic brain injury.
Intranasal COVID-19 vaccine candidate (NT-CoV-2 platform)
A vaccine candidate engineered for intranasal or intramuscular administration, using rapid antigen expression platforms and intranasal formulation approaches intended to elicit mucosal immunity and simplify storage/transport requirements.
Intranasal neurosteroid lead candidate (clinical-stage)
A first-in-class neurosteroid candidate delivered via an intranasal spray-dried nanoparticle formulation and single-use nasal device intended to provide rapid brain absorption for treatment of mild traumatic brain injury.
Intranasal COVID-19 vaccine candidate (NT-CoV-2 platform)
A vaccine candidate engineered for intranasal or intramuscular administration, using rapid antigen expression platforms and intranasal formulation approaches intended to elicit mucosal immunity and simplify storage/transport requirements.
Services
Clinical trial operations and CRO collaboration
Design and operational coordination of early-phase clinical trials (including emergency department implementations) through partnerships with clinical research organizations.
Preclinical formulation and analytical development
Optimization of spray-dried intranasal nanoparticle formulations and development/validation of bioanalytical assays to support PK/PD and toxicology studies.
Vaccine antigen development and intranasal formulation
Collaborative development of spike-protein antigens using rapid CHO-based cell-line generation and evaluation of intranasal vaccine formulations aimed at mucosal immunity.
Clinical trial operations and CRO collaboration
Design and operational coordination of early-phase clinical trials (including emergency department implementations) through partnerships with clinical research organizations.
Preclinical formulation and analytical development
Optimization of spray-dried intranasal nanoparticle formulations and development/validation of bioanalytical assays to support PK/PD and toxicology studies.
Vaccine antigen development and intranasal formulation
Collaborative development of spike-protein antigens using rapid CHO-based cell-line generation and evaluation of intranasal vaccine formulations aimed at mucosal immunity.
Expertise Areas
- Intranasal drug delivery
- Neurosteroid therapeutics for traumatic brain injury
- Clinical trial design and execution in emergency medicine settings
- Vaccine antigen design and intranasal vaccine development
Key Technologies
- Intranasal olfactory/trigeminal transport
- Spray-dried nanoparticle powder formulation
- Single-use intranasal delivery devices
- CHO cell-line antigen expression